Biotechnology

SILVER SPRING, Maryland (Reuter)-U. S. health adviser recommended beautiful first new weight lost in a decade on Tuesday, backing Contrave Orexigen Therapeutics Inc. Was of a trios drug addiction under the weight of the lost nine to come before regulators this year, the food and Drug Administration rejected the two rival medicine last October. THE FDA Panel of experts to be voted 13-7 who lost weight with benefits see Contrave Sur concern about that risk. THE FDA panel usually follow the recommendation. State-of-the-art led must pass 31 January. Shares of Orexigen was always totally immediately after the vote but reserve Arena pharmacy Inc. competitor was 7 percent higher in one commercial and Vivus Inc. rose 11 percent in extended trade. Put Contrave is key to companies based in California, which focuses only on obesity drug and not commodities. According to information of BioMedTracker Contrave, sales could reach $ 1. $ 2 billion by 2018. Face would be the biggest player in a u. s. ...

Maggie Fox, health and Science Editor Maggie Fox, health and Science Editor – Mon Nov 22 6 : 19 pm ET, WASHINGTON (Reuters)-Portland, Oregon, Christopher Goodrich can be expected to stick a needle in her eye. Goodrich hopes one clinical research, which received only in the food and drug administration, only the second research accepted throughout the world to test the human embryonic stem cells in humans, the go-ahead of the first patients enrolled in. Advanced cell technology, a small Massachusetts-based biotechnology company, which has struggled to raise the human embryonic stem cell Lab clinic begins recruitment and Massachusetts patients 12 Oregon rare eye condition, i.e. Stargardt's macular dystrophy. Goodrich, 55, retired last year in his job as a coordinator of Portland State University services veteran's macular dystrophy when his Stargardt viewing experience, and suddenly deteriorated. Like most patients Goodrich had seen his Vision to get steadily worse his young adul...

LOS ANGELES (Reuters) – a key trial Seattle Genetics tests with the patients antibodies targeting cancer n Hodgkin Lymphoma, it was found that more than a third of them achieved the complete remission of their cancer. The company also said it expects to produce drugs now, following the US regulatory authorities brentuximab vedotin (2) years from the date of the first quarter of patients either n Hodgkin Lymphoma or anaplastic large cell Lymphoma (ALCL) that have ceased responding to other therapies. The company had previously said it would take place in the first half of 2011, the consignment. "Our goal should be submitted in the first quarter of the year, and can be placed on the market of an accelerated review in 2011," Seattle Genetics CEO Siegall told Reuters the telephone Clay in the interview. The experiment to compare with another drug brentuximab vedotin, but similar patients full cancellation of the course is typically a single character, he said. The company is dev...

Maggie Fox, health and Science Editor Maggie Fox, health and Science Editor – Mon Nov 22, 2: 21 pm ET, WASHINGTON (Reuters)-the u.s. food and Drug Administration has approved a second human trial of human embryonic stem cell--one testing cells in humans that awful gradually form, the company said on Monday. Massachusetts-based enhanced cell Technology, said it would start testing 12 patients with macular dystrophy Stargardt's stem cell treatment based on it. Human embryonic stem cells shall be approved by the FDA, the second is the subject of this year. Last month, the first patient enrolled in Geron Corp. using it; in people with spinal cords crushed in the investigation. "It is exciting--vindication. All this work really came through, "said Dr. Robert Lanza, Chief Medical Officer of the company, which has struggled to stay solvent gambled controversial in the cells. Stem cells are the cells in the body of the master, all other cells in the source. Supporters of the use ...